A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis.
The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis.
Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.
The panel’s opinion will now be reviewed by the EMA.
In October, U.S. regulators declined to approve sarilumab because of manufacturing deficiencies at a Sanofi plant in France.
Regeneron said in February that it was planning to resubmit a marketing application to the U.S. Food and Drug Administration for sarilumab.
The drug has already been approved by Canadian health regulators to treat rheumatoid arthritis.
Rheumatoid arthritis is the most prominent autoimmune arthritis. It is caused by a defective immune system that causes your defense system to target your joint linings. It affects the wrist and small joints of your hands, including the knuckles, other joints in your fingers and can eventually spread to your knees too.
It is considered one of the most disabling forms of arthritis as it affects both sides of the body, making it different from other forms of arthritis. It can also affect skin, eyes, lungs, heart, blood and even your nerves which is why it is one of the most feared forms of arthritis.
Over the years, several ways of treating rheumatoid arthritis have been discovered. Although there is still no cure for the condition, the treatment can significantly heal those that are newly diagnosed and can slow down the process that in the patients that have been suffering from the condition for a while.
When your immune system attacks your own body, certain chemicals